Nucleophosmin expression in renal cell carcinoma and oncocytoma

Abstract

The objective of this study was to investigate nucleophosmin/B23 (NPM) expression in renal cell carcinomas (RCC) and renal oncocytomas. The expression of NPM was studied by immunohistochemical methods on 59 RCCs, 9 oncocytomas, and 19 tumour-negative renal tissues. The expression was assessed relative to various clinicopathological variables and histological subtypes, to determine its potential role as a prognostic and diagnostic marker. All tumours showed nuclear staining, and a minority also exhibited cytoplasmic immunoreactivity. Two patterns of nuclear staining were observed: nuclear staining with a prominent nucleolus (nucleolar staining) and nuclear staining without a prominent nucleolus. There were significant differences, in both nuclear staining and cytoplasmic NPM expression, between oncocytomas and chromophobe RCCs (p < 0.001) and clear cell RCCs (p < 0.001). Cytoplasmic NPM expression was markedly lower in RCCs than in oncocytomas. A statistically significant correlation was discovered between nucleolar staining and nuclear grade (p < 0.001, r = 0.5). No relationship was found between cytoplasmic expression of NPM and any of the clinicopathological parameters or survival. NPM might be a useful immunohistochemical marker for differential diagnosis between oncocytoma and chromophobe RCC. In addition, increased nucleolar NPM expression in RCCs appears to be associated with tumour progression.

Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis

“…Moreover, NPM was overexpression in thyroid tumors, its dysregulation occurred at protein level and related to an increase of p-Akt level of transformed thyrocytes [ 16 ]. NPM might be a useful immunohistochemical marker for differential diagnosis between oncocytoma and chromophobe renal cell carcinomas (RCCs), and increased nucleolar NPM expression in RCCs appeared to be associated with tumor progression [ 37 ]. All these researches proved the significant value of NPM as a biomarker in the occurrence and progress of solid tumors.…”

Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer

“…Our previous study found that NPM was abnormally overexpressed in MCF-7/MTX cells compared with sensitive cells. Moreover, recent studies have shown that NPM, as non-ribosomal nucleolar phosphoprotein, was high level in a variety of tumors including gastric cancer (28), colon cancer (29), thyroid cancer (30), renal cell carcinoma (31) and even expected as a biomolecular marker for breast cancer (32). In addition, Wang et al (17) found that decreased expression of nucleophosmin/B23 could increase drug sensitivity of adriamycin-resistant Molt-4 leukemia cells.…”

Nucleolin and nucleophosmin expression patterns in pulmonary adenocarcinoma invading the pleura and in pleural malignant mesothelioma

“…The authors also found a correlation between nucleolar nucleophosmin staining and tumor grade. 31 The results from the above-mentioned studies suggest that nucleophosmin expression is highly tumor specific. The lack of differences in nucleophosmin expression between adenocarcinoma and malignant mesothelioma that we found in our study are difficult to explain, but may indicate that this protein is similarly involved in the growth of these two neoplasms.…”

“…Nucleolin expression has been studied in different cancers including breast, 11 prostate, 18 colon, 19 lung, 20 pancreas, 21 stomach, 22 and testicular tumors, 23 while nucleophosmin has been studied in a wide variety of solid tumors including cancer of the lung, 16 bladder, [24][25] oral cavity, 26 colon, 27 liver, [28][29] thyroid 30 and in renal tumors. 31 Only a few studies have focused on the nucleolus in pulmonary tumors. Xu et al found nucleolar size (inconspicuous vs. prominent) to be associated with lymph node and distant metastases of pulmonary adenocarcinoma.…”